Cardiometabolic effects of psychotropic medications.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical risks with no systematic literature search or quantitative synthesis.
PubMed 29320364 · doi:10.1515/hmbci-2017-0065
What was done
This paper reviewed literature on the cardiometabolic adverse effects of psychotropic medications, focusing on mechanisms and risk factors categorized under the components of metabolic syndrome.
What was found
The abstract reports qualitative associations without quantitative data or effect estimates. Commonly used psychotropics—especially antipsychotics, mood stabilizers, and specific antidepressants—were identified as contributing to obesity, dyslipidemia, and insulin resistance. Additionally, stimulants, norepinephrine reuptake inhibitors, select antipsychotics, and valproic acid derivatives were linked to increased blood pressure.
Why it matters
Patients with severe psychiatric disorders face elevated baseline cardiovascular mortality, and psychotropic-induced metabolic adverse effects can compound this risk, underscoring the need for proactive monitoring and clinical management.
Limits
The abstract provides no quantitative data, effect sizes, or specific study sample sizes. As a narrative review, it lacks a systematic search protocol and does not grade the quality of the underlying primary evidence.
Cited by
- supports Many of the mainstream medications for bipolar disorder directly lead to metabolic dysfunction.